









Markets
/
Stocks
/
nasdaq-cdtx
/

Cidara Therapeutics Inc

CDTX

View Detailed Chart

62.900USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

767.96MMarket Cap

LossP/E TTM



Cidara Therapeutics Inc

62.900

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-0.65%

5 Days

+1.70%

1 Month

+28.95%

6 Months

+231.93%

Year to Date

+134.00%

1 Year

+429.46%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts

BUY

Current Rating

59.167

Target Price

-5.94%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Cidara Therapeutics Inc

CDTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(4)

Buy(7)

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.003

Neutral

RSI(14)

69.501

Neutral

STOCH(KDJ)(9,3,3)

66.847

Neutral

ATR(14)

3.964

Low Volatility

CCI(14)

62.266

Neutral

Williams %R

24.229

Buy

TRIX(12,20)

1.951

Sell

StochRSI(14)

28.383

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

62.522

Buy

MA10

62.071

Buy

MA20

57.351

Buy

MA50

41.547

Buy

MA100

31.164

Buy

MA200

25.294

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Ticker SymbolCDTX

CompanyCidara Therapeutics Inc

CEODr. Jeffrey L. (Jeff) Stein, Ph.D.

Websitehttps://www.cidara.com/